Abstract
Individuals with subclinical atrial fibrillation (AF) face an increased risk of thromboembolic events, which may potentially be mitigated through AF screening and subsequent anticoagulation. However, data from randomized clinical trials (RCTs) indicate a lower stroke risk in subclinical AF compared with the clinical phenotype. This—along with the inherent bleeding risk related to anticoagulation—seems to render the net clinical benefit of AF screening less evident. Further, current guidelines recommend consideration of CHA2DS2-VASc score and AF episode duration to guide screening and treatment. These recommendations, in general, lack support and seem questionable in view of the limited RCT data. More evidence is warranted to provide insights into the potential benefits of screening and treatment of screen-detected AF in specific population subgroups and AF phenotypes.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Heart Journal, Supplement |
| Vol/bind | 26 |
| Udgave nummer | suppl. 4 |
| Sider (fra-til) | iv41-iv49 |
| ISSN | 1520-765X |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:Conflict of interest: L.Y.X., O.B.V., and D.E. have no conflicts of interest to report. J.H.S. reports to be a member of Vital Beats and Medtronic advisory boards and to have received speaker honoraria and research grants from Medtronic outside this work. S.Z.D. reports to be a part-time employee of Vital Beats and advisor at Bristol Myers Squibb/Pfizer, not related to this work.
Funding Information:
This work was supported by the European Union\u2019s Horizon 2020 program (grant number 847770) through the AFFECT-EU consortium.
Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.